ImYoo
ImYoo is a US biotech Public Benefit Corporation enabling at-home immune-system sampling: patients self-collect blood samples that are analyzed with single-cell RNA sequencing to produce high-resolution, longitudinal immune profiles.
About
ImYoo is a US biotech Public Benefit Corporation enabling at-home immune-system sampling: patients self-collect blood samples that are analyzed with single-cell RNA sequencing to produce high-resolution, longitudinal immune profiles. It runs a Patient Scientist Network with studies such as lupus treatment monitoring and B-cell depletion.
Capital graph
Founders / team· 2
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- ImYoo
ImYoo is a US biotech Public Benefit Corporation enabling at-home immune-system sampling: patients self-collect blood samples that are analyzed with single-cell RNA sequencing to produce high-resolution, longitudinal immune profiles. It runs a Patient Scientist Network with studies such as lupus treatment monitoring and B-cell depletion.
—
United States
BusinessLatest roundTotal raisedDate- Regard
Uses AI to analyze patient health data, helping physicians save time and improve diagnostic accuracy
Series B · $61M · 2024-07
$61M - Evvy
At-home vaginal microbiome metagenomic sequencing tests and an accompanying prescription care platform
Series B · $59M · 2026-09
$59M - Tiny Health
At-home gut and vaginal microbiome tests, with TinyAI trained on proprietary data giving personalized health recommendations, for consumers and healthcare practitioners
Series B · $46M · 2026-09
$46M
China
BusinessLatest roundTotal raisedDate- DeepInformatics++
AI + digital pathology focused on core diagnostic needs: full-chain digital pathology department solutions incl. smart scanning, QC and multi-cancer analysis; develops the DeepPathAI pathology model.
Series C · 2026-07
— - 透彻未来
AI-based pathology image diagnosis services
Series A · $69M · 2024-06
$69M - 睿心医疗
Developer of AI precision diagnosis and treatment platforms for cardiovascular and cerebrovascular disease and of vascular interventional surgical robots.
Strategic · 2026-07
—
Europe
BusinessLatest roundTotal raisedDate- HyprView
Multimodal photonic imaging + AI medical analysis
Pre-Seed · $2M · 2025-11
$2M - Skin Analytics
AI tool that assists skin cancer detection by identifying skin lesions from images
Series B · $20M · 2025-04
$20M - Oxford Cancer Analytics
AI-based blood tests for cancer detection
Series A · $11M · 2025-01
$11M
Other / unspecified
BusinessLatest roundTotal raisedDate- Nucleai
Uses AI to analyze pathology images for medical research and clinical diagnosis
Undisclosed · $14M · 2024-04
$14M - HoneyNaps
Uses advanced algorithms to analyze sleep data and provide accurate diagnostic insights
Series B · $12M · 2024-05
$12M - Medmain
AI-based cloud platform for digital pathology analysis and remote diagnosis; develops and offers PidPort, an AI-driven cloud system for digital pathology
Undisclosed · $3M · 2025-05
$3M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 22 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.